Associated Papers
Systematic cysteine scanning identifies a druggable pocket in oncogenic KRAS.
van Tienen LM et al.
Cell Chemical Biology, 2026
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
The dynamics of mutational selection in cutaneous squamous carcinogenesis.
Skrupskelyte G et al.
Communications Biology, 2026
A Real-World Experience on the Efficacy of First-Line Treatment with Immune-Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%: The Role of KRAS Mutations.
Motta L et al.
Cancers, 2025
Oral Melanocytic Neoplasms: A Narrative Review.
Maldonado-Mendoza J
Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2025
Tumor mutational burden modulates the prognostic effect of RAS mutations in metastatic colon cancer: mechanistic insights and genotype-phenotype correlations.
Ianniello M et al.
Journal of Translational Medicine, 2025
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer.
Sposito M et al.
Scientific Reports, 2025
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?
William D et al.
Esmo Gastrointestinal Oncology, 2025
Towards Personalized Precision Oncology: A Feasibility Study of NGS-Based Variant Analysis of FFPE CRC Samples in a Chilean Public Health System Laboratory.
Durán-Jara E et al.
Current Issues in Molecular Biology, 2025
Exploring the Impact of TP53 Mutation and Wild-Type Status on the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.
Yakobson A et al.
International Journal of Molecular Sciences, 2025
Evaluation of Bridge Capture technology for mutation profiling in liquid biopsies of metastatic colorectal cancer patients.
Ganesan A et al.
Scientific Reports, 2025
Clinicopathological and molecular characterization of KRAS wild-type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes.
Toriyama K et al.
The Journal of Pathology, 2025
Impacts of co-mutations in oligometastatic and oligoprogressive non-small cell lung cancer with EGFR/ALK mutations-a narrative review of the current literature.
Lim JU et al.
Translational Lung Cancer Research, 2025
Genomic profiling unlocks new treatment opportunities for ampullary carcinoma.
Fabregat-Franco C et al.
Esmo Open, 2025
Somatic Genomic Profiling of Pancreatic Ductal Adenocarcinomas From a Diverse Cohort of Patients.
Riner AN et al.
Pancreas, 2025
DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer.
Tan S et al.
Cancer, 2025
Large-cell Basaloid Adenocarcinoma of the Lung: A Clinicopathologic Study of 12 Cases of a Distinctive Form of Lung Cancer Often Mistaken for Large-cell Neuroendocrine Carcinoma.
Suster D et al.
The American Journal of Surgical Pathology, 2025
Clinicopathological and molecular features of lung cancers associated with cystic airspaces: an analysis of 34 cases.
Zhou F et al.
Journal of Thoracic Disease, 2024
Inflammatory Giant Cell Carcinoma of the Lung: Clinicopathologic, Immunohistochemical, and Next-generation Sequencing Study of 14 Cases.
Suster DI et al.
The American Journal of Surgical Pathology, 2024
Molecular characterization of Chinese patients with small bowel adenocarcinoma.
Jin B et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024
Pan-Cancer Comparative and Integrative Analyses of Driver Alterations Using Japanese and International Genomic Databases.
Horie S et al.
Cancer Discovery, 2024
Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non-small-cell Lung Cancer.
Mathiot L et al.
Clinical Lung Cancer, 2024
Distinct Driver Pathway Enrichments and a High Prevalence of TSC2 Mutations in Right Colon Cancer in Chile: A Preliminary Comparative Analysis.
Tapia-Valladares C et al.
International Journal of Molecular Sciences, 2024
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.
Pillai R et al.
Science Advances, 2024
Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition.
Bando H et al.
Cancer Science, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Hardaker EL et al.
Nature Communications, 2024
A cellular and spatial atlas of TP53 -associated tissue remodeling in lung adenocarcinoma.
Zhao W et al.
Biorxiv : the Preprint Server for Biology, 2024
Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets.
Zhang B et al.
Jto Clinical and Research Reports, 2024
Clinical features and mutation analysis of class 1/2/3 BRAF mutation colorectal cancer.
Huang Y et al.
Chinese Clinical Oncology, 2024
Effects of KRAS Genetic Interactions on Outcomes in Cancers of the Lung, Pancreas, and Colorectum.
Grabski IN et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2024
TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma.
Zhou Y et al.
Journal of Translational Medicine, 2023
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre.
Mosteiro M et al.
Esmo Open, 2023
KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.
Arolt C et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2023
Runx3 Restoration Regresses K-Ras-Activated Mouse Lung Cancers and Inhibits Recurrence.
Lee JY et al.
Cells, 2023
ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.
Lee SH et al.
Cancer Research and Treatment, 2023
Excited-state observation of active K-Ras reveals differential structural dynamics of wild-type versus oncogenic G12D and G12C mutants.
Hansen AL et al.
Nature Structural & Molecular Biology, 2023
Concordance of Targeted Sequencing from Circulating Tumor DNA and Paired Tumor Tissue for Early Breast Cancer.
Huang CC et al.
Cancers, 2023
TP53 germline pathogenic variants in modern humans were likely originated during recent human history.
Kou SH et al.
Nar Cancer, 2023
Clinical significance of genetic profiling based on different anatomic sites in patients with mucosal melanoma who received or did not receive immune checkpoint inhibitors.
Wang HY et al.
Cancer Cell International, 2023
Generation of novel complete HLA class I monoallelic cell lines used in an MHC stabilization assay for neoantigen evaluation.
Iizuka A et al.
Oncology Letters, 2023
Completion of Genetic Testing and Incidence of Pathogenic Germline Mutation among Patients with Early-Onset Colorectal Cancer: A Single Institution Analysis.
Storandt MH et al.
Cancers, 2023
Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.
Varadi M et al.
Cancer Medicine, 2023
KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.
Mirzapoor Abbasabadi Z et al.
Journal of Clinical Laboratory Analysis, 2023
Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR.
Mandell JD et al.
Cancer Research, 2023
Loss of HES1 Expression is Associated with Extracellular Matrix Remodeling and Tumor Immune Suppression in KRAS Mutant Colon Adenocarcinomas.
Wang L et al.
Research Square, 2023
A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability.
Guiley KZ et al.
Cancer Discovery, 2023
Heterogeneity of the cancer cell line metabolic landscape.
Shorthouse D et al.
Molecular Systems Biology, 2022